Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Radio-immunotherapeutics in AML: bridge to transplant

Eunice Wang • 3 Jun 2022
ASCO 2022
Acute Myeloid Leukemia Leukemia

Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, describes early data using an Actinium immunoconjugate to cytoreduce patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) prior to allogeneic stem cell transplantation (alloSCT). In this advanced setting, this novel agent is able to successfully bridge patients to alloSCT and may represent an effective pre-conditioning regimen. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Eunice Wang

2:49
Results of a Phase I trial investigating CYNK-001, a placental NK-cell product, in patients with AML
Eunice Wang • 10 Dec 2023
1:30
A Phase I trial investigating a novel oral FLT3 inhibitor, BMF-500, in FLT3-mutant AML
Eunice Wang • 10 Dec 2023
3:03
The effect of BMI on survival outcomes in adolescents and young adults with AML
Eunice Wang • 10 Dec 2023
Novel targets, combinations & treatments
Eunice Wang et al. • 4 Sep 2023

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals